Capital Advisors Ltd. LLC Boosts Holdings in Abbott Laboratories (NYSE:ABT)

Capital Advisors Ltd. LLC lifted its stake in shares of Abbott Laboratories (NYSE:ABT) by 15.8% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 3,571 shares of the healthcare product maker’s stock after buying an additional 486 shares during the quarter. Capital Advisors Ltd. LLC’s holdings in Abbott Laboratories were worth $474,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently bought and sold shares of the stock. Zhang Financial LLC raised its holdings in Abbott Laboratories by 26.9% in the first quarter. Zhang Financial LLC now owns 5,933 shares of the healthcare product maker’s stock worth $787,000 after purchasing an additional 1,259 shares in the last quarter. Flywheel Private Wealth LLC bought a new stake in shares of Abbott Laboratories during the 1st quarter valued at $214,000. Baker Ellis Asset Management LLC grew its position in shares of Abbott Laboratories by 11.5% in the 1st quarter. Baker Ellis Asset Management LLC now owns 2,596 shares of the healthcare product maker’s stock worth $344,000 after buying an additional 268 shares during the period. Magnolia Private Wealth LLC bought a new position in shares of Abbott Laboratories in the 1st quarter worth about $260,000. Finally, Capital Advisory Group Advisory Services LLC lifted its position in Abbott Laboratories by 2.3% during the 1st quarter. Capital Advisory Group Advisory Services LLC now owns 4,237 shares of the healthcare product maker’s stock valued at $562,000 after acquiring an additional 95 shares during the period. 75.18% of the stock is owned by institutional investors.

Analyst Ratings Changes

ABT has been the subject of a number of analyst reports. Wells Fargo & Company raised their target price on shares of Abbott Laboratories from $136.00 to $147.00 and gave the company an “overweight” rating in a research note on Thursday, April 17th. Barclays raised their price objective on Abbott Laboratories from $158.00 to $159.00 and gave the company an “overweight” rating in a research report on Thursday, April 17th. Raymond James boosted their target price on Abbott Laboratories from $132.00 to $142.00 and gave the stock an “outperform” rating in a report on Thursday, April 17th. Wall Street Zen cut Abbott Laboratories from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, February 12th. Finally, Stifel Nicolaus lifted their price target on Abbott Laboratories from $135.00 to $145.00 and gave the stock a “buy” rating in a research report on Thursday, April 17th. Four equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $142.59.

Abbott Laboratories Trading Up 0.6%

Shares of ABT stock opened at $134.88 on Thursday. The company has a current ratio of 1.60, a quick ratio of 1.14 and a debt-to-equity ratio of 0.32. Abbott Laboratories has a 12-month low of $99.71 and a 12-month high of $141.23. The stock has a market capitalization of $234.67 billion, a P/E ratio of 17.63, a P/E/G ratio of 2.52 and a beta of 0.73. The firm’s 50 day moving average is $131.03 and its 200 day moving average is $126.12.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings results on Wednesday, April 16th. The healthcare product maker reported $1.09 earnings per share for the quarter, beating the consensus estimate of $1.07 by $0.02. Abbott Laboratories had a return on equity of 20.74% and a net margin of 31.95%. The firm had revenue of $10.36 billion for the quarter, compared to analysts’ expectations of $10.38 billion. Research analysts expect that Abbott Laboratories will post 5.14 earnings per share for the current year.

Insider Buying and Selling at Abbott Laboratories

In other Abbott Laboratories news, Director Sally E. Blount sold 2,600 shares of the business’s stock in a transaction dated Wednesday, April 30th. The stock was sold at an average price of $129.66, for a total transaction of $337,116.00. Following the completion of the sale, the director now owns 34,058 shares of the company’s stock, valued at approximately $4,415,960.28. The trade was a 7.09% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 0.46% of the stock is owned by corporate insiders.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.